Back to Dashboard

R3918-PNH-2021

PNH•NCT05133531•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

C5 inhibitor

Mechanism of Action

C5 inhibitor

Sponsor

Unknown

Design

III

Control Arm

Eculizumab

Criteria

Inclusion Criteria

Untreat or Eculizumab stop over 3 m or Ravulizumab stop over 6 m

Age: Phase: III

Exclusion Criteria

Enrollment

Progress0 / 0

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620